Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–95 of 95 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sodium Fluorescein Clear all
Completed No phase listed Observational

Digital Photography to Evaluate Dry Eye

NCT00073099
View directory record Official record
Conditions
Eye Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 4, 2026, 4:15 AM EDT
Not listed Phase 1Phase 2 Interventional

VST-1001 (Dilute Fluorescein) for Lymphatic Mapping & Localization of Lymph Nodes in Patients With Breast Cancer

NCT02294565
View directory record Official record
Conditions
Breast Cancer
Interventions
VST-1001, 99mTc-labeled sulfur colloid
Drug
Lead sponsor
Vestan, Inc.
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Houston, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 27, 2015 · Synced Oct 4, 2026, 4:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ocular Surface Immune Response in Dry Eye Disease

NCT02042820
View directory record Official record
Conditions
Dry Eye Disease
Interventions
In vivo confocal microscopy (IVCM)
Other
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Identification of Nerves Using Fluorescein Sodium

NCT06054178
View directory record Official record
Conditions
Pleomorphic Adenoma of the Parotid, Warthin Tumor, Head and Neck Disorder, Head and Neck, Thyroid Disease, Thyroidectomy
Interventions
Fluorescein Sodium
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 4, 2026, 4:15 AM EDT
Terminated Early Phase 1 Interventional

A Feasibility Study of Confocal Microendoscopy in the Evaluation of Gastrointestinal Neoplasia -Project 1

NCT01384695
View directory record Official record
Conditions
GERD, Barrett's Esophagus
Interventions
Fluorescein, Proflavine hemisulfate
Drug
Lead sponsor
Anandasabapathy, Sharmila, M.D.
Individual
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 4, 2026, 4:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Triton Fundus Autofluorescence and Fluorescein Angiography

NCT03107104
View directory record Official record
Conditions
Medical Need for Fluorescein Angiography Imaging
Interventions
Topcon DRI OCT Triton (plus), TRC-50DX retinal camera
Device
Lead sponsor
Topcon Medical Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 4, 2026, 4:15 AM EDT
Active, not recruiting Phase 2 Interventional

Optical Tissue Identification for Myocardial Architecture

NCT04017975
View directory record Official record
Conditions
Ventricular Septal Defect, Complete Atrioventricular Canal, Tetralogy of Fallot With Pulmonary Stenosis
Interventions
Fluorescite, Cellvizio 100 Series System with Confocal Miniprobes
Drug · Device
Lead sponsor
Aditya Kaza
Other
Eligibility
30 Days to 18 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 4, 2026, 4:15 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

NCT04008121
View directory record Official record
Conditions
Retinopathy, Retinal Vein Occlusion, Diabetic Retinopathy, Macular Degeneration
Interventions
Fluorescein sodium and Zeiss FF450 fundus camera, MB-102 and Zeiss FF450 fundus camera, Fluorescein sodium and commercially available optical angiography imaging system, MB-102 and commercially available optical angiography imaging system
Combination Product
Lead sponsor
MediBeacon
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Results available

Utilization of Confocal Microscopy During Cardiac Surgery

NCT03189134
View directory record Official record
Conditions
Atrial Septal Defect
Interventions
Fluorescite, Cellvizio 100 Series System with Confocal Miniprobes
Drug · Device
Lead sponsor
Aditya Kaza
Other
Eligibility
30 Days to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea

NCT01057147
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Dry Eye
Interventions
rebamipide 2% ophthalmic suspension, placebo eye drops
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
19
States / cities
Mesa, Arizona • Phoenix, Arizona • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2012 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Not applicable Interventional Results available

Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery

NCT01886235
View directory record Official record
Conditions
Recurrent Melanoma, Stage IA Skin Melanoma, Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
Interventions
Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis, Therapeutic Conventional Surgery
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 7, 2020 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Early Phase 1 Interventional Results available

Efficacy of Fluorescein Visualization of the Uterus in Detecting Endometrial Cancer Invasion

NCT01979003
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Fluorescein
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2022 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer

NCT00329368
View directory record Official record
Conditions
Cancer
Interventions
EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC), Interleukin-2, Interferon-alpha
Biological · Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Springfield, Illinois • Lansing, Michigan • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2012 · Synced Oct 4, 2026, 4:15 AM EDT
Recruiting Phase 2 Interventional

A Study of Fluorescein Sodium in People Undergoing Vulvectomy for Extramammary Paget's Disease (EMPD)

NCT06873815
View directory record Official record
Conditions
Extramammary Paget's Disease
Interventions
Fluorescein Sodium
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Fluorescein for Lymphatic Mapping and Sentinel Lymph Node (SLN) Biopsy in Patients With Stage I and II Malignant Melanoma

NCT00847522
View directory record Official record
Conditions
Cancer
Interventions
Fluorescein
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 20, 2017 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Not applicable Interventional

Study Comparing the P200TxE and P200DTx

NCT03964831
View directory record Official record
Conditions
Retinal Disease
Interventions
P200TxE, P200DTx
Device
Lead sponsor
Optos, PLC
Industry
Eligibility
22 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Early Phase 1 Interventional

Intraoperative Imagery of Renal Nodules With Folate-fluorescein Conjugate(EC17)

NCT01778933
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
EC17
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 4, 2026, 4:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Multimodal Ocular Imaging in Neurodegeneration

NCT03699644
View directory record Official record
Conditions
Alzheimer Disease, Alzheimer Dementia, Frontotemporal Dementia
Interventions
Spectral-Domain Optical Coherence Tomography (SD-OCT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Comprehensive Ophthalmic Examination, Fundus Photography
Device · Diagnostic Test
Lead sponsor
University of Michigan
Other
Eligibility
45 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 4, 2026, 4:15 AM EDT
Terminated Not applicable Interventional Results available

Sodium Fluorescein-Guided Resection of Pediatric Neurosurgical Tumors

NCT03752203
View directory record Official record
Conditions
Pediatric Neurosurgical Tumors
Interventions
Sodium Fluorescein, Microscopic Resection
Drug · Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Days to 21 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Ranibizumab and Peripheral Scatter Laser in Patients With Diabetic Macular Edema and Peripheral Nonperfusion

NCT00815360
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
intravitreal injection of ranibizumab, peripheral laser, intravitreal injection of triamcinolone acetonide, macular laser
Drug · Procedure
Lead sponsor
Retina Associates of Florida, P.A.
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 4, 2026, 4:15 AM EDT
Completed No phase listed Observational Results available

Corneal Topographer Fluorescein Patterns

NCT00584285
View directory record Official record
Conditions
Keratoconus
Interventions
Not listed
Lead sponsor
Christine Sindt
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Nov 2, 2018 · Synced Oct 4, 2026, 4:15 AM EDT
Completed Not applicable Interventional

Confocal Endomicroscopy of Pancreatic InVivo

NCT01035008
View directory record Official record
Conditions
Pancreatic Cysts
Interventions
Endoscopic Ultrasound (EUS)
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 4, 2026, 4:15 AM EDT